Aytuğ Üner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aytuğ Üner has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Özet
Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
12 shared publications - Nazan Günel
Department of Medical Oncology, Gazi University, Ankara, Turkey
8 shared publications - Nuriye Özdemir
Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
8 shared publications - Ozan Yazıcı
Department of Medical Oncology, Gazi University, Ankara, Turkey
8 shared publications - Mustafa Benekli
Faculty of Medicine, Department of Medical Oncology, Gazi University, Ankara, Turkey
6 shared publications - Osman Sütcüoğlu
Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey
6 shared publications
Latest Publications
- 1 January 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (05) , 472-477
Prognostic and predictive value of phospho-c-Jun expression in hepatocellular carcinoma patients treated with sorafenib
- 1 January 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (05) , 472-477
Prognostic and predictive value of phospho-c-Jun expression in hepatocellular carcinoma patients treated with sorafenib
- 30 September 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (3) , 459-464
Prostat kanserinde Lutetium-177-PSMA tedavisi: tek merkezli gerçek yaşam deneyimi
Aim: Lutetium-177–labeled PSMA radioligand therapy has emerged as a promising option in metastatic castration-resistant prostate cancer (mCRPC), yet real-world data remain limited. This study aimed to evaluate clinical features, treatment patterns, and predictors of response in patients treated with Lutetium-177-PSMA therapy at a single academic center. Material and Methods: We retrospectively analyzed 49 patients with mCRPC who received Lutetium-177-PSMA between January 2020 and January 2025. Treatment response was defined as a ≥50% decline in PSA (PSA50). Associations between baseline variables and PSA50 were examined using Mann–Whitney U tests, and predictive biomarkers were evaluated by receiver operating characteristic (ROC) analysis. Results: The PSA50 response rate was 41.7%. Lower baseline PSA (p = 0.023), ALP (p = 0.037), and LDH (p = 0.004) levels, and higher hemoglobin (p = 0.024), were significantly associated with response. Hemoglobin demonstrated the highest discriminatory performance (AUC = 0.692), while PSA, ALP, and LDH showed significant but limited predictive value. Treatment was well tolerated, with only one case of grade 3-4 hematologic toxicity. Conclusion: Lutetium-177-PSMA therapy provides clinical benefit in real-world mCRPC patients. Lower tumor burden and preserved hematologic status may predict better biochemical response, with hemoglobin serving as a moderately accurate biomarker. Prospective validation is warranted.
- 30 September 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (3) , 459-464
Prostat kanserinde Lutetium-177-PSMA tedavisi: tek merkezli gerçek yaşam deneyimi
Aim: Lutetium-177–labeled PSMA radioligand therapy has emerged as a promising option in metastatic castration-resistant prostate cancer (mCRPC), yet real-world data remain limited. This study aimed to evaluate clinical features, treatment patterns, and predictors of response in patients treated with Lutetium-177-PSMA therapy at a single academic center. Material and Methods: We retrospectively analyzed 49 patients with mCRPC who received Lutetium-177-PSMA between January 2020 and January 2025. Treatment response was defined as a ≥50% decline in PSA (PSA50). Associations between baseline variables and PSA50 were examined using Mann–Whitney U tests, and predictive biomarkers were evaluated by receiver operating characteristic (ROC) analysis. Results: The PSA50 response rate was 41.7%. Lower baseline PSA (p = 0.023), ALP (p = 0.037), and LDH (p = 0.004) levels, and higher hemoglobin (p = 0.024), were significantly associated with response. Hemoglobin demonstrated the highest discriminatory performance (AUC = 0.692), while PSA, ALP, and LDH showed significant but limited predictive value. Treatment was well tolerated, with only one case of grade 3-4 hematologic toxicity. Conclusion: Lutetium-177-PSMA therapy provides clinical benefit in real-world mCRPC patients. Lower tumor burden and preserved hematologic status may predict better biochemical response, with hemoglobin serving as a moderately accurate biomarker. Prospective validation is warranted.
- 1 March 2024
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 16 (1) , 32-37
The frequency of autoimmune disease in the first degree and other relatives of the breast cancer patients
- 1 March 2024
- Published by Galenos Yayinevi in Ulusal Romatoloji Dergisi
- Vol. 16 (1) , 32-37
The frequency of autoimmune disease in the first degree and other relatives of the breast cancer patients
- Open Access
- 30 October 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma
Introduction: Resistance to immune checkpoint inhibitors (ICI) is a significant issue in metastatic renal cell carcinoma (mRCC), as it is in the majority of cancer types. An important deficiency in immunooncology today is the lack of a predictive factor to identify this patient group. Myeloid-derived suppressor cells (MDSC) are a type of cell that contributes to immunotherapy resistance by inhibiting T cell activity. While it accumulates in the tumor microenvironment and blood, it can also accumulate in lymphoid organs such as the spleen and cause splenomegaly. Therefore we aimed to evaluate the effect of increase in splenic volume, which can be considered as an indirect indicator of increased MDSC cells, on survival outcomes in mRCC patients. Methods: We analyzed 45 patients with mRCC who received nivolumab as a second-line or subsequent therapy. Splenic volume was analyzed from baseline imaging before starting nivolumab and from control imaging performed within the first 6 months of treatment initiation. Additionally, we analyzed how patients’ body mass index (BMI), IMDC risk score, ECOG performance status, nephrectomy status, neutrophil-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR) and sites of metastasis. Results: Median splenic volume change was 10% (ranging from − 22% to + 117%) during follow-up. Change in splenic volume was found to be associated with overall survival (OS) and progression-free survival (PFS) (p = 0.025, 0.04). The median PFS in patients with increased splenic volume was 5 months, while it was 17 months in patients without increased splenic volume. (HR 2.1, 95% CI (1–4), p = 0.04). The median OS in patients with increased splenic volume was 9 months, while it was 35 months in patients without increased splenic volume (HR 2.7, 95% CI (1.1–6.2), p = 0.025). In four patients with decreased splenic volume, neither PFS nor OS could reach the median value. Log-rank p value in respectively (0.015, 0.035), The group in which an increase in volume was accompanied by a high NLR had the shortest survival rate. Basal splenic volume was analyzed separately. However, neither PFS nor OS differed significantly. Conclusion: Our findings suggest that the change in splenic volume throughout immunotherapy regimens may be utilized to predict PFS and OS in mRCC patients undergoing treatment.
- 30 October 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Open AccessThe role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma
Introduction: Resistance to immune checkpoint inhibitors (ICI) is a significant issue in metastatic renal cell carcinoma (mRCC), as it is in the majority of cancer types. An important deficiency in immunooncology today is the lack of a predictive factor to identify this patient group. Myeloid-derived suppressor cells (MDSC) are a type of cell that contributes to immunotherapy resistance by inhibiting T cell activity. While it accumulates in the tumor microenvironment and blood, it can also accumulate in lymphoid organs such as the spleen and cause splenomegaly. Therefore we aimed to evaluate the effect of increase in splenic volume, which can be considered as an indirect indicator of increased MDSC cells, on survival outcomes in mRCC patients. Methods: We analyzed 45 patients with mRCC who received nivolumab as a second-line or subsequent therapy. Splenic volume was analyzed from baseline imaging before starting nivolumab and from control imaging performed within the first 6 months of treatment initiation. Additionally, we analyzed how patients’ body mass index (BMI), IMDC risk score, ECOG performance status, nephrectomy status, neutrophil-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR) and sites of metastasis. Results: Median splenic volume change was 10% (ranging from − 22% to + 117%) during follow-up. Change in splenic volume was found to be associated with overall survival (OS) and progression-free survival (PFS) (p = 0.025, 0.04). The median PFS in patients with increased splenic volume was 5 months, while it was 17 months in patients without increased splenic volume. (HR 2.1, 95% CI (1–4), p = 0.04). The median OS in patients with increased splenic volume was 9 months, while it was 35 months in patients without increased splenic volume (HR 2.7, 95% CI (1.1–6.2), p = 0.025). In four patients with decreased splenic volume, neither PFS nor OS could reach the median value. Log-rank p value in respectively (0.015, 0.035), The group in which an increase in volume was accompanied by a high NLR had the shortest survival rate. Basal splenic volume was analyzed separately. However, neither PFS nor OS differed significantly. Conclusion: Our findings suggest that the change in splenic volume throughout immunotherapy regimens may be utilized to predict PFS and OS in mRCC patients undergoing treatment.
- Open Access
- 3 September 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (5) , 932-939
Long-term outcomes of COVID-19 infection in patients with solid tumors
Objectives: We analyzed the impact of some clinical and disease-specific factors on the longterm outcomes of SARS-CoV-2 infection in patients with solid tumors. Methods: Total of 739 patients with known solid malignancy and infected by SARS-CoV-2 before the beginning of vaccination were examined. Results: Seventy-six cancer patients died from COVID-19 infection-related effects such as mostly pulmonary and cardiovascular system disorders after a median 16-month follow-up (67.1% and 14.5%; respectively). Compared with survivors (n = 468), non-survivors due to COVID-19 infection related effects (n = 76) were more likely to be aged ≥ 65 years and diagnosis with lung cancer (p = 0.01). Also, female patients were at decreased risk of mortality [OR: 0.34 (95% CI: 0.18-0.65)]. Furthermore, patients with tumor stage IV, active/stable/progressive disease and patients receiving active anticancer therapy were at increased risk of mortality (p = 0.01). Conclusions: The patients with aged ≥ 65 years, diagnosed with lung cancer, receiving active anticancer therapy, with active/stable/progressive and advanced cancer stage were at increased risk of mortality from COVID-19 infection in long-term follow-up.
- 3 September 2023
- Published by The European Research Journal in The European Research Journal
- Vol. 9 (5) , 932-939
Open AccessLong-term outcomes of COVID-19 infection in patients with solid tumors
Objectives: We analyzed the impact of some clinical and disease-specific factors on the longterm outcomes of SARS-CoV-2 infection in patients with solid tumors. Methods: Total of 739 patients with known solid malignancy and infected by SARS-CoV-2 before the beginning of vaccination were examined. Results: Seventy-six cancer patients died from COVID-19 infection-related effects such as mostly pulmonary and cardiovascular system disorders after a median 16-month follow-up (67.1% and 14.5%; respectively). Compared with survivors (n = 468), non-survivors due to COVID-19 infection related effects (n = 76) were more likely to be aged ≥ 65 years and diagnosis with lung cancer (p = 0.01). Also, female patients were at decreased risk of mortality [OR: 0.34 (95% CI: 0.18-0.65)]. Furthermore, patients with tumor stage IV, active/stable/progressive disease and patients receiving active anticancer therapy were at increased risk of mortality (p = 0.01). Conclusions: The patients with aged ≥ 65 years, diagnosed with lung cancer, receiving active anticancer therapy, with active/stable/progressive and advanced cancer stage were at increased risk of mortality from COVID-19 infection in long-term follow-up.
- 14 August 2023
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 36 (3) , 249-257
Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy
The aim of our study was to evaluate the association between increased splenic volume (SV) and liver fibrosis indices in colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Patients who received adjuvant oxaliplatin-based regimens with the diagnosis of stage II and III colon cancer were evaluated. Splenic volume measurements, liver function tests, platelet count, and non-invasive liver fibrosis indices [NAFLD fibrosis score (NFS), AST to platelet ratio (APRI), and Fibrosis-4 (FIB-4)] were measured before and after treatment. A 30% increase in SV after chemotherapy compared to baseline was considered increased SV. The rate of increase in SV was 57.7% in the whole group. An increase in SV was shown at a higher rate in patients treated with capecitabine and oxaliplatin (CAPOX) than those treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) (66.3% vs. 36.8%, p = 0.002). Furthermore, the CAPOX regimen (OR: 2.831, 95% CI: 1.125-7.121; p = 0.027), and higher post-treatment FIB-4 score (OR: 3.779; 95% CI:1.537- 9.294, p = 0.004) were determined as independent risk factors for the increased SV. Our study revealed that increased SV had a significant association with higher FIB-4 score in patients treated with oxaliplatin-based chemotherapy.
- 14 August 2023
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 36 (3) , 249-257
Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy
The aim of our study was to evaluate the association between increased splenic volume (SV) and liver fibrosis indices in colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Patients who received adjuvant oxaliplatin-based regimens with the diagnosis of stage II and III colon cancer were evaluated. Splenic volume measurements, liver function tests, platelet count, and non-invasive liver fibrosis indices [NAFLD fibrosis score (NFS), AST to platelet ratio (APRI), and Fibrosis-4 (FIB-4)] were measured before and after treatment. A 30% increase in SV after chemotherapy compared to baseline was considered increased SV. The rate of increase in SV was 57.7% in the whole group. An increase in SV was shown at a higher rate in patients treated with capecitabine and oxaliplatin (CAPOX) than those treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) (66.3% vs. 36.8%, p = 0.002). Furthermore, the CAPOX regimen (OR: 2.831, 95% CI: 1.125-7.121; p = 0.027), and higher post-treatment FIB-4 score (OR: 3.779; 95% CI:1.537- 9.294, p = 0.004) were determined as independent risk factors for the increased SV. Our study revealed that increased SV had a significant association with higher FIB-4 score in patients treated with oxaliplatin-based chemotherapy.
- Open Access
- 27 March 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (2) , 106-111
Prognostic role of preoperative neoadjuvant chemotherapy in patients with tongue cancer
Aim: This study aimed to investigate the relationship between preoperative neoadjuvant chemotherapy (NAC) and overall survival in patients with tongue cancer who underwent glossectomy. Material and Method: The study included 35 tongue cancer patients who underwent glossectomy. Twenty patients did not receive any treatment before surgery (control group). Fifteen patients received two cycles of cisplatin-containing NAC prior to surgery. Five-year overall survival findings were compared between the groups. Results: Median pathological depth of invasion was lower in the NAC group compared to the control group (7 vs. 9 mm, p=0.037). The mortality rate was lower in the NAC group (26.7% vs. 50.0%, p=0.008). Increased depth of invasion was independently associated with increased risk of mortality, while receiving NAC was independently associated with decreased risk of mortality. The risk of mortality was 6.25-fold lower (1/0.16) in the NAC group compared to the control group (HR: 0.16, 95% CI: 0.004-0.72, p=0.017). Conclusion: Patients who underwent NAC plus surgery were associated with a higher probability of 5-year overall survival compared to patients who underwent surgery alone. These findings may be inspiring for the role of NAC prior to surgery in the prognosis of patients with tongue cancer.
- 27 March 2023
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 4 (2) , 106-111
Open AccessPrognostic role of preoperative neoadjuvant chemotherapy in patients with tongue cancer
Aim: This study aimed to investigate the relationship between preoperative neoadjuvant chemotherapy (NAC) and overall survival in patients with tongue cancer who underwent glossectomy. Material and Method: The study included 35 tongue cancer patients who underwent glossectomy. Twenty patients did not receive any treatment before surgery (control group). Fifteen patients received two cycles of cisplatin-containing NAC prior to surgery. Five-year overall survival findings were compared between the groups. Results: Median pathological depth of invasion was lower in the NAC group compared to the control group (7 vs. 9 mm, p=0.037). The mortality rate was lower in the NAC group (26.7% vs. 50.0%, p=0.008). Increased depth of invasion was independently associated with increased risk of mortality, while receiving NAC was independently associated with decreased risk of mortality. The risk of mortality was 6.25-fold lower (1/0.16) in the NAC group compared to the control group (HR: 0.16, 95% CI: 0.004-0.72, p=0.017). Conclusion: Patients who underwent NAC plus surgery were associated with a higher probability of 5-year overall survival compared to patients who underwent surgery alone. These findings may be inspiring for the role of NAC prior to surgery in the prognosis of patients with tongue cancer.
- 26 January 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (2) , 1-10
Greater financial toxicity correlates with increased psychological distress and lower quality of life among Turkish cancer patients
Purpose This study aims to investigate the factors that influence financial toxicity and its effects on both quality of life and psychological distress in Turkish cancer patients. Methods Data from 400 cancer patients receiving chemotherapy at a public university in Turkey was analyzed. The Comprehensive Score for Financial Toxicity (COST), Patient Health Questionnaire for Depression and Anxiety (PHQ-4), and Functional Assessment of Cancer Therapy-General (FACT‐G) were used to measure financial toxicity, psychological distress, and health quality of life, respectively. Results Patients’ median COST score was 22 (SD = 10.1; range: 1–44) and was consistent with mild financial toxicity. Financial toxicity was associated with lower education level (p < 0.001), lower monthly income (p < 0.001), being a woman (p = 0.021), living in another city (p = 0.012), and previous cancer surgery (p = 0.02). A negative and statistically significant correlation was found between financial toxicity and quality of life (r = − 0.139; p = 0.005) and psychological distress (r = − 0.398; p < 0.001). Conclusion This investigation demonstrated that financial toxicity was a significant determinant of quality of life and psychological distress.
- 26 January 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (2) , 1-10
Greater financial toxicity correlates with increased psychological distress and lower quality of life among Turkish cancer patients
Purpose This study aims to investigate the factors that influence financial toxicity and its effects on both quality of life and psychological distress in Turkish cancer patients. Methods Data from 400 cancer patients receiving chemotherapy at a public university in Turkey was analyzed. The Comprehensive Score for Financial Toxicity (COST), Patient Health Questionnaire for Depression and Anxiety (PHQ-4), and Functional Assessment of Cancer Therapy-General (FACT‐G) were used to measure financial toxicity, psychological distress, and health quality of life, respectively. Results Patients’ median COST score was 22 (SD = 10.1; range: 1–44) and was consistent with mild financial toxicity. Financial toxicity was associated with lower education level (p < 0.001), lower monthly income (p < 0.001), being a woman (p = 0.021), living in another city (p = 0.012), and previous cancer surgery (p = 0.02). A negative and statistically significant correlation was found between financial toxicity and quality of life (r = − 0.139; p = 0.005) and psychological distress (r = − 0.398; p < 0.001). Conclusion This investigation demonstrated that financial toxicity was a significant determinant of quality of life and psychological distress.
- Open Access
- 1 January 2023
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 53 (1) , 142-148
LAG-3 expression in tumor microenvironment of triple-negative breast cancer
Background/aim: This study aimed to evaluate the expression of lymphocyte activation gene-3 (LAG-3) and its relationship with programmed cell death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC). Materials and methods: LAG-3 and PD-L1 was evaluated in tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). The chi-square test was used to estimate the associations between LAG-3, PD-L1 and clinicopathological characteristics. Correlation between LAG-3 stromal TIL (sTIL), LAG-3 intraepitelial TIL (iTIL) and PD-L1 was assessed with using the Spearman's correlation coefficient. Survival analysis was performed using the Kaplan-Meier method. Results: The percentages of LAG-3 sTIL+, LAG-3 iTIL+, PD-L1+ tumor cells and PD-L1+ inflammatory cells were 52%, 42%, 14% and 70%, respectively. A strong positive correlation between LAG-3 sTIL and LAG-3 iTIL (r = 0.874, p < 0.001) and a moderate positive correlation between LAG-3 sTIL and PD-L1 (r = 0.584, p < 0.001) were found. LAG-3 and PD-L1 status did not significantly affect overall survival (OS) (HR: 0.56 (95% CI: 0.15-2.11) (p = 0.397), HR: 2.70 (95% CI: 0.56-13.02) (p = 0.215), respectively). Conclusion: High levels of LAG-3 and PD-L1 expression were detected in patients with TNBC. Although their contribution to survival could not be determined, the high expression rates of PD-L1 and LAG-3 may help identify the subgroup of TNBC that would benefit from immunotherapy.
- 1 January 2023
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 53 (1) , 142-148
Open AccessLAG-3 expression in tumor microenvironment of triple-negative breast cancer
Background/aim: This study aimed to evaluate the expression of lymphocyte activation gene-3 (LAG-3) and its relationship with programmed cell death ligand-1 (PD-L1) in triple-negative breast cancer (TNBC). Materials and methods: LAG-3 and PD-L1 was evaluated in tumor-infiltrating lymphocytes (TILs) using immunohistochemistry (IHC). The chi-square test was used to estimate the associations between LAG-3, PD-L1 and clinicopathological characteristics. Correlation between LAG-3 stromal TIL (sTIL), LAG-3 intraepitelial TIL (iTIL) and PD-L1 was assessed with using the Spearman's correlation coefficient. Survival analysis was performed using the Kaplan-Meier method. Results: The percentages of LAG-3 sTIL+, LAG-3 iTIL+, PD-L1+ tumor cells and PD-L1+ inflammatory cells were 52%, 42%, 14% and 70%, respectively. A strong positive correlation between LAG-3 sTIL and LAG-3 iTIL (r = 0.874, p < 0.001) and a moderate positive correlation between LAG-3 sTIL and PD-L1 (r = 0.584, p < 0.001) were found. LAG-3 and PD-L1 status did not significantly affect overall survival (OS) (HR: 0.56 (95% CI: 0.15-2.11) (p = 0.397), HR: 2.70 (95% CI: 0.56-13.02) (p = 0.215), respectively). Conclusion: High levels of LAG-3 and PD-L1 expression were detected in patients with TNBC. Although their contribution to survival could not be determined, the high expression rates of PD-L1 and LAG-3 may help identify the subgroup of TNBC that would benefit from immunotherapy.
- 20 September 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (11) , 494.e1-494.e10
Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma
- 20 September 2022
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 40 (11) , 494.e1-494.e10
Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma